Centers for Cardiovascular Research, Inflammation, Translational & Clinical Lung Research, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, United States.
Department of Cell Biology and Genetics, School of Basic Medical Science, Shanxi Medical University, Taiyuan, China.
Front Immunol. 2020 Oct 19;11:554301. doi: 10.3389/fimmu.2020.554301. eCollection 2020.
The mechanisms that underlie various inflammation paradoxes, metabolically healthy obesity, and increased inflammations after inflammatory cytokine blockades and deficiencies remain poorly determined. We performed an extensive -omics database mining, determined the expressions of 1367 innate immune regulators in 18 microarrays after deficiencies of 15 proinflammatory cytokines/regulators and eight microarray datasets of patients receiving Mab therapies, and made a set of significant findings: 1) proinflammatory cytokines/regulators suppress the expressions of innate immune regulators; 2) upregulations of innate immune regulators in the deficiencies of IFNγ/IFNγR1, IL-17A, STAT3 and miR155 are more than that after deficiencies of TNFα, IL-1β, IL-6, IL-18, STAT1, NF-kB, and miR221; 3) IFNγ, IFNγR and IL-17RA inhibit 10, 59 and 39 proinflammatory cytokine/regulator pathways, respectively; in contrast, TNFα, IL-6 and IL-18 each inhibits only four to five pathways; 4) The IFNγ-promoted and -suppressed innate immune regulators have four shared pathways; the IFNγR1-promoted and -suppressed innate immune regulators have 11 shared pathways; and the miR155-promoted and -suppressed innate immune regulators have 13 shared pathways, suggesting negative-feedback mechanisms in their conserved regulatory pathways for innate immune regulators; 5) Deficiencies of proinflammatory cytokine/regulator-suppressed, promoted programs share signaling pathways and increase the likelihood of developing 11 diseases including cardiovascular disease; 6) There are the shared innate immune regulators and pathways between deficiency of TNFα in mice and anti-TNF therapy in clinical patients; 7) Mechanistically, up-regulated reactive oxygen species regulators such as myeloperoxidase caused by suppression of proinflammatory cytokines/regulators can drive the upregulation of suppressed innate immune regulators. Our findings have provided novel insights on various inflammation paradoxes and proinflammatory cytokines regulation of innate immune regulators; and may re-shape new therapeutic strategies for cardiovascular disease and other inflammatory diseases.
各种炎症悖论、代谢健康肥胖以及炎症细胞因子阻断和缺乏后炎症增加的潜在机制仍不清楚。我们进行了广泛的组学数据库挖掘,确定了 15 种促炎细胞因子/调节剂缺乏和 8 个 Mab 治疗患者微阵列数据集后 18 个微阵列中 1367 种固有免疫调节剂的表达,并得出了一系列重要发现:1)促炎细胞因子/调节剂抑制固有免疫调节剂的表达;2)IFNγ/IFNγR1、IL-17A、STAT3 和 miR155 缺乏时固有免疫调节剂的上调多于 TNFα、IL-1β、IL-6、IL-18、STAT1、NF-κB 和 miR221 缺乏时的上调;3)IFNγ、IFNγR 和 IL-17RA 分别抑制 10、59 和 39 个促炎细胞因子/调节剂途径;相反,TNFα、IL-6 和 IL-18 每种途径仅抑制四到五个途径;4)IFNγ 促进和抑制的固有免疫调节剂有四个共同途径;IFNγR1 促进和抑制的固有免疫调节剂有 11 个共同途径;miR155 促进和抑制的固有免疫调节剂有 13 个共同途径,提示固有免疫调节剂保守调控途径存在负反馈机制;5)促炎细胞因子/调节剂抑制、促进的程序共享信号通路,并增加包括心血管疾病在内的 11 种疾病的发病几率;6)在小鼠 TNFα 缺乏和临床患者抗 TNF 治疗之间存在共同的固有免疫调节剂和途径;7)机制上,促炎细胞因子/调节剂的抑制导致髓过氧化物酶等活性氧调节因子的上调,可驱动被抑制的固有免疫调节剂的上调。我们的研究结果为各种炎症悖论和促炎细胞因子对固有免疫调节剂的调控提供了新的见解,并可能为心血管疾病和其他炎症性疾病重塑新的治疗策略。